Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4178256 in Healthy Participants
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate how well LY4178256 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to check how much LY4178256 gets into the bloodstream and how long it takes the body to eliminate it. For each participant, the study will last about 7 months and will include either 7 or 12 visits depending on the assigned treatment.
Official title: A Phase 1, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4178256 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
88
Start Date
2026-07
Completion Date
2028-02
Last Updated
2026-07-13
Healthy Volunteers
Yes
Conditions
Interventions
LY4178256
Administered intravenously (IV)
Placebo
Administered IV
Locations (2)
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States
ICON
Salt Lake City, Utah, United States